Duragesic and Apixaban drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Duragesic (fentanyl) and Apixaban (apixaban). Common drug interactions include disease progression among females and acute respiratory failure among males.

The phase IV clinical study analyzes what interactions people have when they take Duragesic and Apixaban. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Duragesic?

Duragesic has active ingredients of fentanyl. eHealthMe is studying from 66,597 Duragesic users. Check the latest studies of Duragesic.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

On Jul, 27, 2026

11 people who take Duragesic and Apixaban together, and have interactions are studied.

Duragesic and Apixaban drug interactions.

What are the common drug interactions of Duragesic and Apixaban, by gender? *:

female:

Disease progression
Death
Hypersensitivity
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Malignant neoplasm progression (cancer tumour came back)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Pyrexia (fever)

male:

Acute respiratory failure
Aspartate aminotransferase increased
Metabolic encephalopathy (disorder or disease of the brain due to the body's disability to use energy)
Metastases to spine (cancer spreads to spine)
Oedema peripheral (superficial swelling)
Pelvic pain
Pulmonary embolism (blockage of the main artery of the lung)
Pyrexia (fever)
Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
Tachyarrhythmia (disturbance of the heart rhythm in which the heart rate is abnormally increased)

What are the common drug interactions of Duragesic and Apixaban, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Disease progression
Hypercapnia (too much smoke)
Hypoxia (low oxygen in tissues)
Iron deficiency anaemia
Leukopenia (less number of white blood cells in blood)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Metabolic encephalopathy (disorder or disease of the brain due to the body's disability to use energy)
Metastases to spine (cancer spreads to spine)
Oedema peripheral (superficial swelling)
Pelvic pain

50-59:

Pyrexia (fever)

60+:

Death
Disease progression
Hypersensitivity
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Malignant neoplasm progression (cancer tumour came back)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

What are the existing conditions these people have? *

Pain: 7 people, 63.64%
Constipation: 5 people, 45.45%
Nausea (feeling of having an urge to vomit): 3 people, 27.27%
Stress And Anxiety: 3 people, 27.27%
Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 27.27%
Multiple Myeloma (cancer of the plasma cells): 3 people, 27.27%
Nausea And Vomiting: 2 people, 18.18%
Dyspnea (difficult or laboured breathing): 2 people, 18.18%
High Blood Pressure: 2 people, 18.18%
Hypersensitivity: 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Duragesic and Apixaban?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously